NEOS - Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com Editas Provides Update Axsome Suffers Setback
Analysis of top Seeking Alpha coverage: Aradigm
Today we will discuss the much-anticipated FDA briefing documents for Aradaigm’s (ARDM) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11th.
Following the release of the documents, ARDM shares have tumbled more than 40%. We have gone through the briefing documents and we do not see any surprises. We began coverage on ARDM last month and back then we had noted that a potential approval was not priced into the stock. However, we had noted